Search Results 121-130 of 18324 for alopecia
... alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled. For ...
03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Patients with Grade 2 neuropathy are eligible but ...
... alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated. Patient has had major surgery within 14 days prior to starting study drug or ...
Patients with vitiligo or alopecia; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; Any chronic skin ...
... Alopecia areata, Diffuse capillary malformation with overgrowth, Vulvar skin disorder, Blue rubber bleb nevus syndrome, Vascular anomaly, Vascular ...
Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. * True abstinence ...
... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...
0 for phase II part 2 (except neuropathy [see exclusion criterion below] and alopecia). Neuropathy ≥ Grade 3. Clinically significant (that is, active) ...
... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...
... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!